Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Seminars in Arthritis & Rheumatism

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.semarthrit.2015.11.012PMID 26743073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.

  2015cited by this paper
• Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

  2015cited by this paper
• The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria

  2014cited by this paper
• Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases.

  2013cited by this paper
• Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet’s Disease

  2013cited by this paper
• Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab

  2013cited by this paper
• Refractory neuro-Behçet treated by tocilizumab: a case report.

  2012cited by this paper
• Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

  2012cited by this paper
• Tocilizumab treatment for neuro-Behcet's disease, the first report.

  2012cited by this paper
• A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

  2012cited by this paper
• Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.

  2011cited by this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2010cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cited by this paper
• International Uveitis Study Group (IUSG) Clinical Classification of Uveitis

  2008cited by this paper
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease.

  2008cited by this paper
• EULAR recommendations for the management of Behçet disease

  2008cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

  2005cited by this paper
• The Behcet's disease activity index.

  2004cited by this paper
• The Behçet's disease activity index.

  2003cited by this paper
• Cytokine profile in Behçet's disease patients

  2002cited by this paper
• Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease.

  1992cited by this paper

• SER recommendations on treatment of refractory Behçet's syndrome.

  2024cites this paper
• Recomendaciones SER sobre el tratamiento del síndrome de Behçet refractario

  2024cites this paper
• Infliximab versus interferon-alpha in the treatment of Behçet's Syndrome: Clinical data from the BIO-BEHÇET'S randomised controlled trial.

  2024cites this paper
• Biologic therapy in large and small vessels vasculitis, and Behçet's disease: Evidence- and practice-based guidance.

  2023cites this paper
• Intestinal Behcet’s Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents

  2023cites this paper
• Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients

  2023cites this paper
• Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease

  2023cites this paper
• Comparing biologic options for the management of Behcet’s disease-related uveitis

  2023cites this paper
• Tocilizumab and its usage for skin diseases

  2022cites this paper
• Behçet uveitis: Current practice and future perspectives

  2022cites this paper
• Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China

  2021cites this paper
• Experimental Therapeutic Solutions for Behcet’s Disease

  2021cites this paper
• Treatment of Neuro-Behçet’s Disease

  2021cites this paper
• Biologic treatments in Behçet's disease

  2021cites this paper
• French recommendations for the management of Behçet’s disease

  2021cites this paper
• Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.

  2020cites this paper
• Management of Behcet's syndrome.

  2020cites this paper
• Effectiveness of tocilizumab for Behcet disease complicated by amyloidosis in the intestinal tract

  2020cites this paper
• An Overview of Conventional and Recent Treatment Options for Behcet’s Disease

  2020cites this paper
• Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents

  2020cites this paper
• Tocilizumab and its usage for skin diseases.

  2020cites this paper
• Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review

  2020cites this paper
• Clinical Manifestations and Management of Pediatric Behçet’s Disease

  2020cites this paper
• Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.

  2019cites this paper
• The use of biologic agents in the management of uveitis

  2019cites this paper
• Update on the treatment of Behçet’s syndrome

  2019cites this paper
• The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review

  2019cites this paper
• Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan

  2019cites this paper
• [Prognostic factors of ocular involvement in Behçet's disease].

  2019cites this paper
• Expert opinion on the use of biological therapy in non-infectious uveitis

  2019cites this paper
• Behçet’s Syndrome and the Nervous System Involvement

  2019cites this paper
• Novel Approaches to the Treatment of Noninfectious Uveitis

  2019cites this paper
• Chapter 3 Etiology , Immunopathogenesis and Biomarkers in Behçet ’ s disease

  2018cites this paper
• Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study

  2018cites this paper
• Management of Behçet's disease

  2018cites this paper
• [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].

  2018cites this paper
• Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease.

  2018cites this paper
• Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy

  2018influential citation
• Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease

  2018cites this paper
• Conventional and biological immunosuppressants in vasculitis.

  2018cites this paper
• Behçet syndrome: a contemporary view

  2018cites this paper
• IL-6: To immunity and beyond

  2018cites this paper
• [Ocular manifestations in Behçet's disease].

  2018cites this paper
• Avis d’experts pour le traitement des uvéites non infectieuses

  2018cites this paper
• Update on the Medical Management of Gastrointestinal Behçet's Disease

  2017cites this paper
• Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review

  2017cites this paper
• Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review

  2017cites this paper
• An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review

  2017cites this paper
• Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

  2017cites this paper
• Updated treatment strategies for intestinal Behçet’s disease

  2017cites this paper
• IL-6 blockade in the management of non-infectious uveitis

  2017cites this paper
• Evidence for choosing biologic disease-modifying anti-rheumatic drugs in the treatment of Behçet disease.

  2017cites this paper
• Knitting the Threads of Silk through Time: Behçet's Disease—Past, Present, and Future

  2017cites this paper
• Pharmacologic Therapy of Ocular Disease

  2017cites this paper
• The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 Are Novel Biomarkers of Specific Endogenous Uveitic Entities.

  2016cites this paper
• Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳s disease.

  2016cites this paper
• Pharmacologic Treatment of Noninfectious Uveitis.

  2016cites this paper
• One year in review 2016: Behçet's syndrome.

  2016cites this paper
• Tocilizumab-induced mucosal ulcers in a patient with relapsing polychondritis: An adverse drug reaction?

  2016cites this paper